RxDoctor Payments Data

Sanjay Adhia, MD

Forensic Psychiatry · Houston, TXNPI 1467658930

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Johnson & Johnson at 26.2% of the total.

$1,080in general payments, 2019–2025

Across 53 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$283
  • Alkermes, Inc.$159
  • EMD Serono, Inc.$115
  • Otsuka America Pharmaceutical, Inc.$86
  • AbbVie$85
  • Vanda Pharmaceuticals Inc.$71
  • plus $282 from 11 others

What the payments were for

  • Food & beverage$1,05097%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few forensic psychiatry providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,983
Medicare patients
57
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl46$16,428
DayvigoLemborexant21$7,613
BelsomraSuvorexant11$5,728
Aripiprazole34$3,837
Trazodone Hcl219$2,967
Duloxetine Hcl142$2,708
Bupropion XlBupropion Hcl78$2,005
Buspirone Hcl79$1,506
Quetiapine Fumarate ErQuetiapine Fumarate11$1,317
Prazosin Hcl40$1,300
Clonazepam47$687
Doxepin Hcl40$623
Propranolol Hcl21$602
Sertraline Hcl74$523
Divalproex Sodium ErDivalproex Sodium12$503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckBelsomra$11$5,72811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few forensic psychiatry providers in Texason file to place this against a meaningful peer group, so we don't.

Other forensic psychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →